<TEXT>&#2;<DATELINE>2004-09-12</DATELINE><TITLE>To Test Or Not To Test?</TITLE><BODY>The use of genetic tests to improve diagnosis and to screen out potential non-responders to costly biologic therapies would seem like a prudent investment, but the practice is far from mainstream. To payers, the issue is more than black and white.&#3;</BODY></TEXT>